(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2016 (12.05.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/073918 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61P 27/02* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2015/059575

(22) International Filing Date:
6 November 2015 (06.11.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/076,770 7 November 2014 (07.11.2014) US
62/088,061 5 December 2014 (05.12.2014) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(71) Applicants *(for US only)*: **SALLSTIG, Peter** [US/US]; c/o Alcon Research Ltd, 4056 South Fwy, Fort Worth, Texas 76134 (US). **SCHMIDT, Werner** [US/US]; c/o Alcon Research Ltd, 6201 South Fwy, Fort Worth, Texas 76134 (US).

(72) Inventors: **GEKKIEVA, Margarita**; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **WARBURTON, James**; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **WEICHSELBERGER, Andreas**; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) Agents: **DERRY, Jason J.** et al.; 6201 South Freeway, Fort Worth, Texas 76134 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: METHODS FOR TREATING OCULAR DISEASES

FIG. 1



(57) **Abstract**: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

WO 2016/073918 A1